BPMX News and Press, BioPharmX Corporation. Common From 09/09/19

SAN JOSE, Calif. , Sept. 9, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports financial results for the fiscal quarter ended July 31, 2019 . Recent H...

BioPharmX Corporation ( BPMX ) is a pharmaceutical company that announced on Monday 25 June that it had positive topline results from its Phase 2b trial of BPX-04 for Papulopustular Rosacea (BPX-04 being a topical gel, and papulopustular rosacea being a skin disorder causing redness, swellin...

Small biotech company BioPharmX Corp (NYSE:BPMX) has been on a tear in Tuesday’s trading session, and BPMX stock rose by as much as 30% on the back of highly positive news about its topical minocycline gel BPX-04. Highly Positive Results According to the announcement made today, ...

Nano cao BioPharmX (NYSEMKT: BPMX ) is up  60%  premarket on robust volume in response to positive results from a Phase 2b clinical trial, PRISM , evaluating topical minocycline gel BPX-04 in patients with moderate-to-severe papulopustular rosacea , a skin disorder akin to acne...

SAN JOSE, Calif. , June 25, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced positive results from its Phase 2b clinical trial of BPX-04 1 , a novel to...

BioPharmX (NYSEMKT: BPMX ): Q1 Non-GAAP EPS of -$0.36; GAAP EPS of -$0.38 misses by $0.10 . More news on: BioPharmX Corporation, Earnings news and commentary, , Read more ...

SAN JOSE, Calif. , June 11, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports financial results for the quarter ended April 30, 2019. Recent...

BioPharmX ( BPMX -6.2% ) reports that the last patient in its Phase 2b clinical trial evaluating topical gel BPX-04 for the treatment of papulopustular rosacea has completed the last clinical visit. More news on: BioPharmX Corporation, Healthcare stocks news, Read more ...

SAN JOSE, Calif. , May 22, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, announced today that the last patient in the Company's Phase 2b clinical trial of BPX-04 1 ...

BioPharmX (NYSEMKT: BPMX ) -3% . More news on: BioPharmX Corporation, STMicroelectronics N.V., UP Fintech Holding Limited, Stocks on the move, Read more ...